Logo image
Se connecter
Neuro-inflammatory risk factors for treatment failure in "early second stage" sleeping sickness patients treated with pentamidine
Article de revue   Avec comité de lecture

Neuro-inflammatory risk factors for treatment failure in "early second stage" sleeping sickness patients treated with pentamidine

Veerle Lejon, Dominique Legros, Alexia Savignoni, Marc Gastellu Etchegorry, Dawson Mbulamberi et Philippe Büscher
Journal of neuroimmunology, Vol.144(1-2), pp.132-138
01/11/2003
PMID: 14597107

Résumé

Adolescent Adult Animals Cerebrospinal Fluid Proteins - biosynthesis Cerebrospinal Fluid Proteins - blood Cerebrospinal Fluid Proteins - cerebrospinal fluid Child Child, Preschool Female Humans Immunoglobulin M - biosynthesis Immunoglobulin M - blood Immunoglobulin M - cerebrospinal fluid Latex Fixation Tests Leukocyte Count Male Melarsoprol - therapeutic use Middle Aged Pentamidine - therapeutic use Recurrence Risk Factors Treatment Failure Trypanosoma brucei gambiense - drug effects Trypanosoma brucei gambiense - growth & development Trypanosoma brucei gambiense - immunology Trypanosomiasis, African - cerebrospinal fluid Trypanosomiasis, African - drug therapy Trypanosomiasis, African - parasitology Trypanosomiasis, African - pathology

Indicateurs

1 Consultations de la notice

Détails

Logo image